Inhibikase Therapeutics, Inc.IKTNASDAQ
LOADING
|||
PB Ratio: Premium Valuation
Trending higher, above historical average.
Left:
||||
Price-to-book ratio
Latest
2.38
↑ 109% above average
Average (8y)
-26.82
Historical baseline
Range
High:7.09
Low:-101.98
CAGR
NaN%
Modest growth trend
| Period | Value | Change |
|---|---|---|
| 2024 | 2.38 | +285.2% |
| 2023 | 0.62 | +3.0% |
| 2022 | 0.60 | -14.0% |
| 2021 | 0.70 | -90.2% |
| 2020 | 7.09 | +131.1% |
| 2019 | -22.76 | +77.7% |
| 2018 | -101.98 | -43.8% |
| 2017 | -70.91 | -24.2% |
| 2016 | -57.11 | - |